Bessemer Group Inc. Has $72,000 Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Bessemer Group Inc. lowered its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 55.0% in the fourth quarter, Holdings Channel reports. The firm owned 2,178 shares of the biotechnology company’s stock after selling 2,664 shares during the quarter. Bessemer Group Inc.’s holdings in Exelixis were worth $72,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MML Investors Services LLC boosted its holdings in shares of Exelixis by 9.9% in the 3rd quarter. MML Investors Services LLC now owns 22,958 shares of the biotechnology company’s stock valued at $596,000 after buying an additional 2,077 shares during the last quarter. M&T Bank Corp grew its position in shares of Exelixis by 12.7% in the 3rd quarter. M&T Bank Corp now owns 14,433 shares of the biotechnology company’s stock valued at $374,000 after acquiring an additional 1,621 shares during the period. Sanctuary Advisors LLC raised its holdings in shares of Exelixis by 42.7% in the 3rd quarter. Sanctuary Advisors LLC now owns 39,261 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 11,757 shares during the period. Tidal Investments LLC lifted its stake in Exelixis by 2.3% in the 3rd quarter. Tidal Investments LLC now owns 36,366 shares of the biotechnology company’s stock valued at $944,000 after purchasing an additional 823 shares during the last quarter. Finally, Tri Ri Asset Management Corp bought a new position in Exelixis during the third quarter worth about $4,396,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 27th. Truist Financial upped their price objective on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. Stephens reissued an “equal weight” rating and issued a $29.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Finally, Barclays upped their target price on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $37.59.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total transaction of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at $13,231,886.40. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the transaction, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last 90 days. Corporate insiders own 2.85% of the company’s stock.

Exelixis Trading Up 0.1 %

EXEL stock opened at $36.19 on Friday. The firm has a 50-day moving average price of $36.37 and a 200-day moving average price of $34.18. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $40.02. The stock has a market capitalization of $10.13 billion, a P/E ratio of 20.45, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.